153 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
25 Apr 24
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
7:47am
in Earlier-Line Multiple Myeloma and Breyanzi in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and Positive Proof of Concept for Opdualag … with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
2 Feb 24
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
7:46am
indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who
8-K
EX-99.1
ea8y0 6xitn5q2j7jbp
8 Jan 24
Regulation FD Disclosure
10:29am
8-K
EX-99.1
afxcl tw7ko
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
wpm2 2mqftr73
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
8-K
EX-99.1
3715t
10 Jan 22
Regulation FD Disclosure
6:59am
8-K
EX-99.1
ozmjvq0r0z4v
16 Nov 21
Regulation FD Disclosure
9:20am
8-K
EX-99.1
l79dr ntp1va0s5lml
28 Jul 21
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
7:33am